Renal Dysfunction Does Not Alter the Pharmacokinetics or LDL‐Cholesterol Reduction of Atorvastatin

  title={Renal Dysfunction Does Not Alter the Pharmacokinetics or LDL‐Cholesterol Reduction of Atorvastatin},
  author={Ralph H. Stern and B-B Yang and M. Horton and S Moore and Robert B. Abel and Stephen C. Olson},
  journal={The Journal of Clinical Pharmacology},
  • R. Stern, B-B Yang, S. Olson
  • Published 1 September 1997
  • Biology, Medicine, Chemistry
  • The Journal of Clinical Pharmacology
The objective of this study was to determine the effects of renal dysfunction on the steady‐state pharmacokinetics and pharmacodynamics of atorvastatin, a 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitor. Nineteen subjects with calculated creatinine clearances ranging from 13 mL/min to 143 mL/min were administered 10 mg atorvastatin daily for 2 weeks. Pharmacokinetic parameters and lipid responses were analyzed by regression on calculated creatinine clearance. Correlations between… 
Safety and Efficacy of Fluvastatin in Hyperlipidemic Patients With Chronic Renal Disease
Fluvastatin treatment significantly improved lipid parameters in patients with chronic renal disease and hyperlipidemia and was well tolerated, with no adverse effects on renal function and no muscular toxicity.
Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients.
  • R. Lins, K. Matthys, N. Lameire
  • Medicine, Biology
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2003
While subtle differences may exist in the metabolic processing of atorvastatin in haemodialysis patients, active drug did not accumulate nor did it show enhanced elimination, and levels were comparable to those measured in healthy volunteers, therefore there is no need to adapt atorVastatin dosage in this particular patient population.
Clinical Pharmacokinetics of Atorvastatin
Atorvastatin is subject to metabolism by CYP3A4 and cellular membrane transport by OATP C and P-glycoprotein, and drug-drug interactions with potent inhibitors of these systems, such as itraconazole, nelfinavir, ritonavir, cyclosporin, fibrates and grapefruit juice, have been demonstrated.
Development of a Population Pharmacokinetic Model for Atorvastatin Acid and Its Lactone Metabolite
A population pharmacokinetic model was developed and validated to describe atorvastatin acid and its lactone metabolite concentration-time data and it was demonstrated that the model adequately described the pharmacokinetics of both species.
Pharmacokinetics of Cerivastatin in Renal Impairment Are Predicted by Low Serum Albumin Concentration Rather Than by Low Creatinine Clearance
It is concluded that low serum albumin concentration rather than low creatinine clearance predicts the pharmacokinetics of cerivastatin in renal impairment.
A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.
Atorvastatin was effective in achieving target LDL-cholesterol levels in a high proportion of the dyslipidemic CAPD patients studied at doses that are well tolerated.
A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment
DDI data from healthy volunteers may represent a worst‐case scenario for clinically derisking P‐gp and BCRP substrates in the setting of RI, and data from DABI, RSV, and ATV suggest an impact of RI on intestinal P‐ gp, and potentially B CRP activity.
Safety of HMG-CoA Reductase Inhibitors: Focus on Atorvastatin
Atorvastatin is well tolerated in long-term treatment of dyslipidemia and is characterized by a safety profile similar to the other available statins.
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.
Estimated GFR improved in both treatment groups but was significantly greater with 80 mg than with 10 mg, suggesting this benefit may be dosage related, and the expected 5-yr decline in renal function was not observed.


Single‐dose pharmacokinetics of 14C‐lovastatin in chronic renal failure
Results indicate that patients with severe renal dysfunction have altered elimination kinetics of lovastatin, and total inhibitors in plasma and total radioactivity were similarly elevated in patients with chronic renal failure.
Single‐Dose Pharmacokinetics of Pravastatin and Metabolites in Patients with Renal Impairment
This single‐dose study demonstrates that pravastatin pharmacokinetics were not affected in patients with renal impairment, probably because of its dual route of elimination.
Effect of Age and Gender on Pharmacokinetics of Atorvastatin in Humans
It is unclear whether these age‐ and gender‐related differences in the pharmacokinetics of atorvastatin will be clinically important, and results of subsequent safety and efficacy trials should help clarify the clinical significance of these pharmacokinetic differences.
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.
Atorvastatin was well tolerated by hyperlipidemic patients, had an acceptable safety profile, and provided greater reduction in cholesterol than other previously reported HMG-CoA reductase inhibitors.
Drug Dosing in Renal Insufficiency
  • R. Talbert
  • Medicine, Biology
    Journal of clinical pharmacology
  • 1994
Drug dosing in renal insufficiency needs to be individualized whenever possible to optimize therapeutic outcomes and to minimize toxicity. Although a number of published tables that provide dosing
Effect of age and gender on atorvastatin pharmacokinetics in humans
  • J Gun Pharmacol
  • 1996
Development and validation of an enzyme inhibition assay for quantitation of CI-981 in human plasma labstracti
  • Pharm Res
  • 1993
Single-dose pharmacokinetics of ‘4C-lovastatin in chronic renal failure
  • Gun Pharmacol Ther 1991;50:437-441
  • 1991